Compare Palo Alto Networks Inc (PANW) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Palo Alto Networks Inc trades at $372.48 (market cap $324.77B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Palo Alto Networks Inc is far larger — about 43.2× Spyre Therapeutics Inc. Common Stock's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palo Alto Networks Inc for 82 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PANW | SYRE | |
|---|---|---|
Market Cap | $324.77B | $7.52B |
Volume | 3,473,783 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $419.91 | $108.92 |
52-Week Low | $141.67 | $22.18 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $324.20B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks (PANW) trades at $375.04, down 7.13% over the past day but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and positive sentiment from 64 buy ratings. Recent earnings beats and robust revenue growth to $9.22B in 2025 highlight fundamental strength, though valuation ratios remain elevated with a P/E of 992.58. The company's AI-driven security platform and continuous defense services are key growth drivers, positioning it well in the cybersecurity sector.
Outlook: PANW's AI integration and platformization strategy support long-term growth, with a consensus price target of $400.05 offering ~6.7% upside. Risks include premium valuation, rising costs, and competitive pressures. Investors should weigh strong fundamentals against high multiples.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
